Qlife has signed a letter of intent with a top-20 global Pharma company to explore a potential commercial collaboration

Qlife has been in discussions with a top-20 global Pharma company to explore opportunities for the sales, distribution, and marketing of the Egoo Health platform, as well as to advance a potential commercial collaboration. The parties have signed a letter of intent (LOI); however, due to the early stage of negotiations, they have agreed to keep the company's identity confidential.

Qlife is actively pursuing a partnership strategy and, with recent advancements in the Egoo Health product lines, expects to establish one or more partnerships during 2025. These collaborations will focus on the commercialization of specific disease areas within the Egoo Health platform.

“We are pleased to see growing interest in the Egoo Health platform, particularly as we transition the company toward commercialization. We believe it is realistic for the company to establish partnerships with leading companies in specific disease fields this year. This LOI represents an important first step in executing our partnership strategy.”- says Thomas Warthoe CEO of Qlife.

This disclosure contains information that Qlife Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 28-01-2025 09:00 CET.

For more information please contact:

Thomas Warthoe, CEO
tw@egoo.health
+45 21 63 35 34

About Egoo Health

Egoo Health enables advanced clinical-grade biomarker testing at home. The aim is to give people access to important health data at the clinical-grade level. Egoo Health is an integrated platform, consisting of a small diagnostic device, a blood-to-plasma collector, a disposable capsule that contain test reagents for a specific biomarker and the Egoo smartphone app that operates the system and can share data with health authorities.